Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$13.27 USD
-0.33 (-2.43%)
Updated May 31, 2024 04:00 PM ET
After-Market: $13.44 +0.17 (1.28%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
DAWN 13.27 -0.33(-2.43%)
Will DAWN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DAWN
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
Biotech ETF Tops in June: 5 Stocks That Outperform
Other News for DAWN
Analysts Are Bullish on Top Healthcare Stocks: Biomea Fusion (BMEA), Day One Biopharmaceuticals (DAWN)
Day One Announces Sale of Priority Review Voucher for $108 Million
Day One Biopharmaceuticals Capitalizes on Priority Review Sale
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M